Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • British Heart Foundation

    - PMLiVE

    Medscape Cardiology: Leading the Future of Heart Failure Education at HFSA 2025

    Medscape Cardiology | theheart.org is proud to be at the forefront of the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM), September 26–29, 2025, in Minneapolis, MN! With...

    Medscape Education

    Bayer symbol

    Bayer’s Kerendia granted FDA approval for new heart failure indication

    Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

    - PMLiVE

    UK researchers uncover first new asthma and COPD attack treatment in 50 years

    The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

    Bayer symbol

    Bayer presents positive results for Kerendia in late-stage heart failure study

    Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%

    - PMLiVE

    J&J to expand cardiovascular capabilities with V-Wave acquisition worth up to $1.7bn

    The company’s medtech division will gain access to a cardiovascular implant device for heart failure

    - PMLiVE

    UK study reveals previously unknown genetic causes of colorectal cancer

    The third most commonly diagnosed cancer globally is responsible for more than 44,000 new cases in the UK every year

    Bayer symbol

    Bayer shares promising results for Kerendia in phase 3 heart failure study

    Approximately 55% of heart failure patients have an LVEF of at least 40%

    - PMLiVE

    Study reveals GSK’s new recombinant shingles vaccine could reduce dementia risk

    Shingrix reduced dementia diagnoses by 17% compared to Merck & Co’s Zostavax after six years

    - PMLiVE

    Novo Nordisk’s Ozempic associated with cognitive benefits in diabetes patients

    Researchers from the University of Oxford analysed records from more than 100 million patients in the US

    - PMLiVE

    New phase 2 study launched to evaluate triple drug combination in pancreatic cancer

    The PRIMUS-006 study will evaluate Lilly/Genentech’s Gemzar in combination with Merck’s Keytruda and Immodulon’s IMM-101

    - PMLiVE

    Study reveals third COVID-19 vaccine dose improves defence in vulnerable patients

    Approximately 90% of patients who received a third dose developed significant levels of antibodies

    - PMLiVE

    Researchers’ new vaccine technology shows efficacy against broad range of coronaviruses

    The vaccine provided protection against coronaviruses that have not yet emerged

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links